Corporate Update – Hanall Biopharma (009420.KS)
On Friday, 23 October 2026, Hanall Biopharma’s shares slipped ‑2.66 % during a 24‑hour trading window that closed at 12:18 PM Central Europe. At the close, the stock traded at KRW 40,200 per share, a modest decline from its previous levels. With a circulating supply of approximately 52.4 million shares, the company’s market capitalisation currently stands at KRW 2.1 trillion. In the past day, roughly KRW 4.5 billion of Hanall Biopharma shares changed hands across the Korean exchanges.
Since the close of last month, Hanall Biopharma has experienced a sharper decline of ‑13.52 %, signalling a cumulative downturn that investors are monitoring closely. The 200‑day simple moving average sits at KRW 51,878.75, offering a long‑term benchmark that the current price has breached by over KRW 11,700. The company’s highest valuation over the previous 52 weeks reached KRW 73,000 on 27 May 2026, while its 52‑week low fell to KRW 32,950 on 27 October 2025, underscoring the volatility that has accompanied its recent performance.
Comparative Performance of Peer Securities
For context, the performance of related stocks over the same 24‑hour period is as follows:
| Stock | Ticker | 24‑Hour Movement | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|---|
| Gs Engineering & Construct | 006360.KS | 0 % | KRW 29,500 | KRW 2.5 trillion | 25.17 |
| Hyundai Elevator | 017800.KS | ‑1.32 % | KRW 65,800 | KRW 2.5 trillion | 6.81 |
| Korean Reinsurance | 003690.KS | +1.2 % | KRW 14,110 | KRW 2.5 trillion | 5.93 |
While Gs Engineering & Construct remained flat, Hyundai Elevator’s modest decline aligns with the broader downturn observed in the Korean market, whereas Korean Reinsurance experienced a slight rebound. These comparative figures help investors gauge whether Hanall Biopharma’s decline is isolated or part of a sector‑wide trend.
Company Overview and Strategic Pipeline
Hanall Biopharma Co., Ltd. is a South Korean pharmaceutical firm founded in 1973 and headquartered in Seoul. It specialises in the research, development, and commercialization of a diverse array of therapeutic agents, targeting both domestic and international markets. Its product pipeline is notable for the breadth of indications it covers:
- HL161 – An anti‑FcRn antibody aimed at treating autoimmune disorders.
- HL036 – An anti‑TNF bio‑ophthalmic solution for dry eye disease.
- HL186 / HL187 – Agents under investigation for recurrent or intractable cancers.
- HL040 – A dual‑indication therapy for hypertension and dyslipidemia.
- HL068 – A drug designed for hypertension management.
- HL018 – An obesity‑treating compound.
- IM156 – A novel oncology therapeutic.
The company’s commitment to expanding its portfolio is evident in its active development of multiple candidates, each positioned to address unmet medical needs across a spectrum of diseases. Hanall Biopharma’s official website, www.hanall.co.kr , provides detailed updates on clinical trial progress, regulatory milestones, and partnership opportunities.
Market Implications
The recent decline in Hanall Biopharma’s share price reflects a combination of short‑term market sentiment and long‑term strategic considerations. Investors will likely scrutinise:
- Pipeline Progress – Any forthcoming data from clinical trials, especially for HL161 and HL036, could sway investor confidence.
- Regulatory Developments – Approvals or delays from Korean or international authorities may influence valuation.
- Sector Dynamics – The stability of peer securities suggests that sector‑specific risks are moderate, yet company‑specific factors remain pivotal.
Despite the current downturn, Hanall Biopharma’s extensive pipeline and established market presence provide a foundation for potential rebound. Analysts will monitor upcoming quarterly reports and product announcements to assess whether the market will revalue the company’s future prospects.
This article is intended to provide a concise, data‑driven overview of Hanall Biopharma’s recent performance and strategic positioning within the Korean pharmaceutical landscape.
